Sernova Corp. · ISIN: CA81732W1041 · EQS - Company News

Sernova Investor Conference Call Previously Scheduled for September 15 Now Rescheduled for September 22

LONDON, Ontario; WINDHAM COUNTY, Connecticut – September 14, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has rescheduled the investor and analyst conference call previously scheduled for September 15 at 10 a.m. Eastern Time. The call will now occur on September 22 at 10 a.m. Eastern Time.  The business strategy and update call remains as scheduled for October 5, 2023. This call will introduce the newl...

TSX:SVA Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Sernova Corp.

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (3)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
14 September 2023 10:06PM
Sernova Investor Conference Call Previously Scheduled for September 15 Now Rescheduled for September 22
CA81732W1041
LONDON, Ontario; WINDHAM COUNTY, Connecticut – September 14, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has rescheduled the investor and analyst conference call previously scheduled for September 15 at 10 a.m. Eastern Time. The call will now occur on Sep...
Sernova Corp.
About the publication
13 September 2023 01:01PM
Sernova to Host Investor Calls to Introduce Newly Appointed CEO and Provide Business Update
CA81732W1041
- Introduction of New CEO Cynthia Pussinen and Recently Appointed Chief Business Officer, Dr. Modestus Obochi, on September 15, 2023 - - Business Update, Strategy & Outlook Call on October 5, 2023 - LONDON, Ontario; WINDHAM COUNTY, Connecticut – September 13, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage compa...
Sernova Corp.
About the publication
03 May 2023 01:01PM
Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications
CA81732W1041
LONDON, Ontario – May 3, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN) to evaluate the use of Sernova’s Cell Pouch System™ in combination with AstraZeneca’s novel th...
Sernova Corp.
About the publication
03 May 2023 01:01PM
Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications
CA81732W1041
LONDON, Ontario – May 3, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN) to evaluate the use of Sernova’s Cell Pouch System™ in combination with AstraZeneca’s novel th...
Sernova Corp.
About the publication
10 April 2023 01:05PM
Sernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the Med
CA81732W1041
LONDON, Ontario – April 10, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced that President and Chief Executive Officer, Dr. Philip Toleikis, will present at the upcoming annual Cell & Gene Meeting on the Med to be held April 12-14, 2023 at the Hotel Arts Bar...
Sernova Corp.
About the publication
10 April 2023 01:05PM
Sernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the Med
CA81732W1041
LONDON, Ontario – April 10, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced that President and Chief Executive Officer, Dr. Philip Toleikis, will present at the upcoming annual Cell & Gene Meeting on the Med to be held April 12-14, 2023 at the Hotel Arts Bar...
Sernova Corp.
About the publication
22 March 2023 12:04PM
Abstract on First Cohort of its Phase 1/2 Study Involving Islet Transplantation into Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions
CA81732W1041
Sernova Announces Abstract on First Cohort of its Phase 1/2 Study Involving Islet Allotransplantation into Pre-vascularized Cell PouchTM Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions 2023 LONDON, Ontario – March 22, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage com...
Sernova Corp.
About the publication
22 March 2023 12:04PM
Sernova: Abstract on First Cohort of its Phase 1/2 Study Involving Islet Transplantation into Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions
CA81732W1041
Sernova Announces Abstract on First Cohort of its Phase 1/2 Study Involving Islet Allotransplantation into Pre-vascularized Cell PouchTM Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions 2023 LONDON, Ontario – March 22, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage com...
Sernova Corp.
About the publication
14 March 2023 12:05PM
Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit
CA81732W1041
First pre-clinical data presentation of Sernova’s Cell Pouch with Evotec’s iPSC derived islet-like cluster technology for type 1 diabetes (T1D) LONDON, Ontario – March 14, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that an abstract has been selected for an ...
Sernova Corp.
About the publication
14 March 2023 12:05PM
Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit
CA81732W1041
First pre-clinical data presentation of Sernova’s Cell Pouch with Evotec’s iPSC derived islet-like cluster technology for type 1 diabetes (T1D) LONDON, Ontario – March 14, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that an abstract has been selected for an ...
Sernova Corp.
About the publication
08 March 2023 01:05PM
Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
CA81732W1041
Third patient now implanted with higher capacity, 10-chamber Cell Pouch Company anticipates first interim data from second cohort in Q4, 2023  LONDON, Ontario – March 8, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that the first two patients in the second ...
Sernova Corp.
About the publication
08 March 2023 01:05PM
Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
CA81732W1041
Third patient now implanted with higher capacity, 10-chamber Cell Pouch Company anticipates first interim data from second cohort in Q4, 2023  LONDON, Ontario – March 8, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that the first two patients in the second ...
Sernova Corp.
About the publication
02 March 2023 01:05PM
Sernova to Participate in Upcoming Roth and Oppenheimer Investor Conferences
CA81732W1041
- Sernova provides warrant update LONDON, Ontario – March 2, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be participating in the upcoming 35th Annual Roth Conference being held March 12-14, 2023 and the Oppenheimer 33rd Annual Healthcare Conference,...
Sernova Corp.
About the publication
02 March 2023 01:05PM
Sernova to Participate in Upcoming Roth and Oppenheimer Investor Conferences
CA81732W1041
- Sernova provides warrant update LONDON, Ontario – March 2, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be participating in the upcoming 35th Annual Roth Conference being held March 12-14, 2023 and the Oppenheimer 33rd Annual Healthcare Conference,...
Sernova Corp.
About the publication
30 January 2023 01:35PM
Sernova Announces Advancements with its Novel Cell Pouch System(TM) to Preserve Thyroid Function Following Total Thyroidectomy
CA81732W1041
Preclinical proof of concept study demonstrates that thyroid auto-transplantation into the Cell Pouch can restore thyroid hormone production following removal of the thyroid gland Sernova has engaged with regulatory authorities towards initiating clinical development of a prospective therapy for hypothyroidism LONDON, Ontario – January 30, 2023 – ...
Sernova Corp.
About the publication
10 January 2023 01:05PM
Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
CA81732W1041
Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes  First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization to treat patients wit...
Sernova Corp.
About the publication
06 December 2022 02:01PM
Sernova Announces CEO Succession Plan and Expanded Management Team
CA81732W1041
The Company is recruiting a new CEO for its next stage of growth - Dr. Toleikis, President and CEO, to transition to Chief Technology Officer upon new appointment LONDON, Ontario -- December 6, 2022 -- Sernova Corp. (Sernova) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that, as...
Sernova Corp.
About the publication
06 December 2022 02:01PM
Sernova Announces CEO Succession Plan and Expanded Management Team
CA81732W1041
The Company is recruiting a new CEO for its next stage of growth - Dr. Toleikis, President and CEO, to transition to Chief Technology Officer upon new appointment LONDON, Ontario -- December 6, 2022 -- Sernova Corp. (Sernova) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that, as...
Sernova Corp.
About the publication
24 February 2022 01:31PM
Sernova Ranks Among Top 50 Performing Companies on the 2022 TSX Venture List
CA81732W1041
Sernova awarded top performer status for two years standing LONDON, ONTARIO - February 24, 2022 - Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine and cell therapy therapeutics company focused on developing a potential 'functional cure' for type 1 diabetes (T1D) and other chronic diseases, is pleased ...
Sernova Corp.
About the publication
05 January 2022 03:25PM
Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference
CA81732W1041
LONDON, ONTARIO - January 5, 2022 - Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine and cell therapy therapeutics company focused on developing a potential 'functional cure' for type 1 diabetes (T1D) and other chronic diseases, is pleased to announce that new interim results from the ongoing safety, t...
Sernova Corp.
About the publication
16 December 2021 12:05PM
Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium
CA81732W1041
LONDON, ONTARIO - December 16, 2021 - Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine and cell therapy therapeutics company focused on developing a potential 'functional cure' for type 1 diabetes (T1D) and other chronic diseases, is pleased to announce that Dr. Piotr Witkowski, principal investigator ...
Sernova Corp.
About the publication
16 November 2021 12:05PM
Sernova to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
CA81732W1041
LONDON, ONTARIO, CANADA - November 16, 2021 - Sernova Corp. (TSX-V:SVA)(FSE/XETRA:PSH)(OTCQB:SEOVF), a leading clinical-stage company focused on regenerative medicine therapeutics, today announced that Dr. Philip Toleikis, President and CEO, will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum o...
Sernova Corp.
About the publication
17 May 2021 03:55PM
Sernova to Present at Global Partnership Family Office - HealthCare & Biotechnology TSX Showcase
CA81732W1041
DGAP-Media / 17.05.2021 / 15:55 LONDON, ON - May 17, 2021 -- Sernova Corp. (TSX-V:SVA)(FSE/XETRA:PSH)(OTCQB:SEOVF), a leading clinical-stage company focused on regenerative medicine therapeutics, today announced that Dr. Philip Toleikis, President and CEO, will present at the virtual Global Partnership Family Office - Healthcare & Biotec...
Sernova Corp.
About the publication
More Sernova Corp related information
Type Total Last Made by Go to
Corporate Research 3 27th September 2024 EQS Group AG Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN